Multiple sclerosis: a practical overview for clinicians
Open Access
- 4 July 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 95 (1) , 79-104
Abstract
Multiple sclerosis (MS) is the commonest disabling neurological condition to afflict young adults and therefore has a high social burden. Over several decades, there has been a considerable progress in the understanding of the disease pathogenesis as well as in the clinical management of MS patients. The emphasis in managing MS patients has shifted to multidisciplinary teams working in specialist groups. A review of the literature was conducted using MedLine to identify recent advances in MS. The current consensus is that MS is an autoimmune disease triggered by environmental agents acting in genetically susceptible people. Based on that concept, new methods of immune intervention procedures have been introduced into clinical practice. Licensed first-line disease-modifying therapies reduce the MS attack or relapse rate by a third and delaying short-term disease progression. More effective therapies have emerged; however, these are associated with increased risks. New clinical and pathological insights are making us question the aetiology and pathogenesis of MS. The recognition of pathological heterogeneity has raised the question of whether MS is a single disease entity or a syndrome. Recent evidence suggests that the pathological subtype may predict therapeutic response to specific therapies. A new novel auto-antibody has defined a subset of neuromyelitis optica or Devic's disease as being distinct from MS. This is an attractive concept that is not widely accepted. The observation that MS progresses despite immunosuppressive therapy suggests that MS may be a neurodegenerative disease with overlapping immune activation possibly in response to the release of central nervous system auto-antigens. The development of neuroprotective therapies for MS is required to prevent the devastating effects of long-term disability as a result of progressive disease.Keywords
This publication has 69 references indexed in Scilit:
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Epstein–Barr virus infection is not a characteristic feature of multiple sclerosis brainBrain, 2009
- Clinical implications of a possible role of vitamin D in multiple sclerosisJournal of Neurology, 2009
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple SclerosisArchives of Neurology, 2009
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialThe Lancet Neurology, 2008
- Dysregulated Epstein-Barr virus infection in the multiple sclerosis brainJournal of Experimental Medicine, 2007
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983